Of these, 35 patients (21%) were excluded due to failure to meet the inclusion and exclusion criteria: untreated active hepatitis (10 of the 35 patients, 28.6%), untreated brain metastases (seven patients, 20%), creatinine clearance less than 50 mL/min (five patients, 14.3%), active autoimmune disease or corticotherapy >10 mg prednisone (or equivalent)/day within 14 days previous to the start of treatment (five patients, 14.3%), known EGFR/ALK actionable mutations or non-squamous histology with unknown EGFR/ALK status (four patients, 11.4%), or PS ECOG greater than 2 (four patients, 11.4%). This evidence concerns the gene ALK and autoimmune disease.